Biomatics Capital
  • Portfolio
  • Team
  • News
  • Contact
  • Investor Portal
Select Page

Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471

by bizlift | Jun 17, 2019 | Compass Press Releases, Portfolio News

Twist Bioscience Launches Mouse Exome to Power Genetic Research

by bizlift | Jun 17, 2019 | Portfolio News, Twist Press Releases

Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association

by bizlift | Jun 15, 2019 | Editas Press Releases, Portfolio News

BlackThorn Therapeutics Closes $76 Million Series B to Advance Targeted Therapeutics for Mental Health

by bizlift | Jun 13, 2019 | BlackThorn Press Releases, Portfolio News

eGenesis Appoints Ariel Jasie as Chief Business Officer and General Counsel

by bizlift | Jun 11, 2019 | eGenesis Press Releases, Portfolio News

Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs

by bizlift | Jun 11, 2019 | Denali Press Releases, Portfolio News

« Older Entries
Next Entries »
© Copyright 2025 Biomatics Capital